These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39394621)

  • 1. [Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)].
    ; ;
    Zhonghua Wai Ke Za Zhi; 2024 Nov; 62(11):984-995. PubMed ID: 39394621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review.
    Tang H; Cao Y; Jian Y; Li X; Li J; Zhang W; Wan T; Liu Z; Tang W; Lu S
    Biosci Trends; 2022 May; 16(2):130-141. PubMed ID: 35431288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition)].
    ; ;
    Zhonghua Wai Ke Za Zhi; 2023 Dec; 61(12):1035-1045. PubMed ID: 37932138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
    Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
    Li X; Xu J; Gu X; Chen L; Wu Q; Li H; Bai H; Yang J; Qian J
    Front Immunol; 2021; 12():740790. PubMed ID: 34733279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
    Yang Y; Sun J; Wu M; Lau WY; Zheng S; Wang XH; Chen X; Fan J; Dong J; Cai J; Chen M; Chen Y; Cheng Z; Dai C; Shan J; Du CY; Fang C; Hu H; Ji Z; Jia W; Li G; Li J; Li J; Liu C; Liu F; Ma Y; Mao Y; Niu Z; Shen J; Shi J; Shi X; Song W; Sun HC; Tan G; Tao R; Wang X; Wen T; Wu L; Xia J; Xiang BD; Yan M; Ying M; Zhang L; Zhang X; Zeng ZC; Zhang Y; Zhang Z; Zhou J; Zhou C; Zhou J; Zhou L; Zhou X; Zhu J; Zhu Z; Zhang Q; Li Q; Cheng S
    Liver Cancer; 2022 Dec; 11(6):511-526. PubMed ID: 36589726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Therapeutic Options for Advanced Hepatocellular Carcinoma.
    Ma YS; Liu JB; Wu TM; Fu D
    Cancer Control; 2020; 27(3):1073274820945975. PubMed ID: 32799550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
    Chen J; Zhang D; Yuan Y
    Clin Exp Med; 2023 Jul; 23(3):579-590. PubMed ID: 36018466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities.
    Martin SP; Mehta N; Emamaullee J
    Liver Transpl; 2024 Jul; 30(7):742-752. PubMed ID: 38345379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
    Mohr R; Jost-Brinkmann F; Özdirik B; Lambrecht J; Hammerich L; Loosen SH; Luedde T; Demir M; Tacke F; Roderburg C
    Front Immunol; 2021; 12():652172. PubMed ID: 33859646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):16-34. PubMed ID: 36948846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy.
    Yamamura K; Beppu T; Miyata T; Okabe H; Nitta H; Imai K; Hayashi H; Akahoshi S
    Anticancer Res; 2022 Jan; 42(1):35-44. PubMed ID: 34969706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two cases.
    Ning C; Liu G; Zhang J; Yang X; Xu Y; Zhao H
    Front Immunol; 2023; 14():1159885. PubMed ID: 37228608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.
    Xu G; Cui L; Li J; Wang Q; Li P; Xia X; Yi X; Guan Q; Xu J
    Clin Transl Med; 2022 Oct; 12(10):e1086. PubMed ID: 36245284
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
    Sun Y; Zhang W; Bi X; Yang Z; Tang Y; Jiang L; Bi F; Chen M; Cheng S; Chi Y; Han Y; Huang J; Huang Z; Ji Y; Jia L; Jiang Z; Jin J; Jin Z; Li X; Li Z; Liang J; Liu L; Liu Y; Lu Y; Lu S; Meng Q; Niu Z; Pan H; Qin S; Qu W; Shao G; Shen F; Song T; Song Y; Tao K; Tian A; Wang J; Wang W; Wang Z; Wu L; Xia F; Xing B; Xu J; Xue H; Yan D; Yang L; Ying J; Yun J; Zeng Z; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhou J; Zhu X; Zou Y; Dong J; Fan J; Lau WY; Sun Y; Yu J; Zhao H; Zhou A; Cai J
    Liver Cancer; 2022 Jun; 11(3):192-208. PubMed ID: 35949289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.